drugset
drugset / Trial / NCT03186040

Open-label Clinical Trial of Lacosamide in ALS

NCT03186040 ↗

Phase 1/2 Completed 7 enrolled Chiba University
NaSingle-groupOpen-labelTreatment

Summary

Lacosamide is administered for patients with amyotrophic lateral sclerosis (ALS).

Timeline

Start
2017-07-13
Primary completion
2020-04-30
Completion
2020-05-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Lacosamide Other / unclassified 400 mg —

Indications

amyotrophic lateral sclerosis